RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer
Charlotte K. Kindt, Sidse Ehmsen, Sofie Traynor, Benedetta Policastro, Nikoline Nissen, Mie K. Jakobsen, Monique F. Hundebøl, Lene E. Johansen, Martin Bak, Elsa Arbajian, Johan Staaf, Henrik J. Ditzel, Carla L. Alves · 2025
Read RET inhibition overcomes resistance to combined CDK4/6 inhibitor and endocrine therapy in ER+ breast cancer by Charlotte K. Kindt, Sidse Ehmsen, Sofie Traynor, Benedetta Policastro, Nikoline Nissen, Mie K. Jakobsen, Monique F. Hundebøl, Lene E. Johansen, Martin Bak, Elsa Arbajian, Johan Staaf, Henrik J. Ditzel, Carla L. Alves (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11808005.txt.
Description
Charlotte K Kindt and co-authors report a study, dated 2024 in its text, on beating drug resistance in a common form of breast cancer. Many such cancers are fed by hormones and are treated with hormone therapy plus a drug that slows cell growth. Most tumors in time stop responding, so new options are badly needed.
The team found a growth switch called RET turned up in cells that resist the paired treatment. Blocking RET with a drug already approved for other uses slowed those cells and made lab-grown tumor samples from patients respond again. Patient data also linked high RET levels with worse outcomes. The authors argue that testing RET could help choose who might gain from adding the blocker.
Catalog record
| CREATOR | Charlotte K. Kindt, Sidse Ehmsen, Sofie Traynor, Benedetta Policastro, Nikoline Nissen, Mie K. Jakobsen, Monique F. Hundebøl, Lene E. Johansen, Martin Bak, Elsa Arbajian, Johan Staaf, Henrik J. Ditzel, Carla L. Alves |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |